Examining the technical indicators, the weekly MACD remains bullish, signalling ongoing positive momentum in the short term, while the monthly MACD shows a mildly bearish stance, suggesting some caution over a longer horizon. The Relative Strength Index (RSI) does not currently provide a definitive signal on either weekly or monthly charts, indicating a neutral momentum phase. Bollinger Bands on both weekly and monthly timeframes lean mildly bullish, implying moderate upward price volatility within established ranges.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- New profitability achieved
- Growth momentum building
- Under-the-radar entry
Daily moving averages for Divis Laboratories maintain a bullish posture, supporting the short-term price strength despite recent minor declines. The KST (Know Sure Thing) indicator presents a bullish weekly signal but shifts to mildly bearish on the monthly scale, reinforcing the mixed momentum narrative. Dow Theory analysis adds further complexity, showing a mildly bearish weekly trend contrasted by a mildly bullish monthly trend. Meanwhile, On-Balance Volume (OBV) lacks a clear weekly trend but is bullish on the monthly chart, suggesting accumulation over a longer period.
From a price perspective, the stock’s 52-week high stands at ₹7,077.70, with a low of ₹4,941.70, and today’s trading range has been between ₹6,457.70 and ₹6,553.60. These levels highlight a relatively tight trading band in recent sessions, reflecting consolidation after prior gains. The market capitalisation grade remains at 1, indicating a particular scale within its sector, while the Mojo Score adjustment to 64.0 and a grade change from Buy to Hold on 18 Nov 2025 reflect the technical parameter changes rather than fundamental shifts.
In terms of returns, Divis Laboratories has shown varied performance relative to the Sensex benchmark. Over the past week and month, the stock has recorded negative returns of -0.90% and -2.17% respectively, while the Sensex posted positive returns of 0.96% and 0.86% in the same periods. Year-to-date, Divis Laboratories has delivered a 6.15% return compared to the Sensex’s 8.36%. Over longer horizons, the stock’s 1-year return of 12.45% surpasses the Sensex’s 9.48%, and its 3-year return of 96.67% significantly outpaces the Sensex’s 37.31%. The 5-year and 10-year returns also demonstrate strong relative performance, with Divis Laboratories at 87.57% and 471.83% respectively, compared to the Sensex’s 91.65% and 232.28%.
Holding Divis Laboratories from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- Peer comparison ready
- Superior options identified
- Cross market-cap analysis
Overall, the technical landscape for Divis Laboratories indicates a nuanced momentum shift with mixed signals across key indicators. The weekly bullishness in MACD and moving averages contrasts with mildly bearish monthly signals, suggesting investors should monitor these parameters closely for further developments. The stock’s relative performance against the Sensex over multiple timeframes underscores its resilience within the Pharmaceuticals & Biotechnology sector, though recent short-term returns have shown some softness. This technical adjustment invites a cautious but attentive approach to the stock’s evolving price dynamics.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
